REYON Pharmaceutical Valuation
Is A102460 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of A102460 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: A102460 (₩13780) is trading above our estimate of fair value (₩2618)
Significantly Below Fair Value: A102460 is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for A102460?
Other financial metrics that can be useful for relative valuation.
What is A102460's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | ₩252.74b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 3x |
Enterprise Value/EBITDA | 69.2x |
PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does A102460's PE Ratio compare to its peers?
Company | Forward PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 19.1x | ||
A009290 Kwang Dong Pharmaceutical | 7.4x | n/a | ₩273.8b |
A005500 Samjin Pharmaceuticals | 11.6x | n/a | ₩252.9b |
A271980 Jeil PharmaceuticalLtd | 48.4x | n/a | ₩242.5b |
A000020 Dongwha Pharm.Co.Ltd | 8.8x | n/a | ₩241.7b |
A102460 REYON Pharmaceutical | 70.5x | n/a | ₩252.7b |
Price-To-Earnings vs Peers: A102460 is expensive based on its Price-To-Earnings Ratio (70.5x) compared to the peer average (19.1x).
Price to Earnings Ratio vs Industry
How does A102460's PE Ratio compare vs other companies in the KR Pharmaceuticals Industry?
Price-To-Earnings vs Industry: A102460 is expensive based on its Price-To-Earnings Ratio (70.5x) compared to the KR Pharmaceuticals industry average (16.6x).
Price to Earnings Ratio vs Fair Ratio
What is A102460's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 70.5x |
Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate A102460's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.